Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yang Cheng Lee"'
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background This study is aimed toward an analysis of the variations in lung cancer incidence and mortality, adjusted by population factors (age, gender, and year), between administrative areas. Methods This is a retrospective study, using 20
Externí odkaz:
https://doaj.org/article/287f254fcb7843758a2570718ee4a12e
Autor:
Hsin-Yu Kuo, Meng-Zhi Han, Chih-Hsiang Liao, Yih-Jyh Lin, Chung-Teng Wang, Shang-Hung Chen, Ting-Tsung Chang, Po-Jun Chen, Sheng-Hsiang Lin, Chiung-Yu Chen, Chiao-Hsiung Chuang, I-Chin Wu, Juei-Seng Wu, Tzu-Chun Hong, Ming-Tsung Hsieh, Yang-Cheng Lee, Hung-Tsung Wu, Hong-Ming Tsai
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2263 (2022)
Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investi
Externí odkaz:
https://doaj.org/article/ebb2164eecf94db09388c555197a1482
Publikováno v:
BMJ Open, Vol 10, Iss 5 (2020)
Objectives Two oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively. The aim of this study were
Externí odkaz:
https://doaj.org/article/8975e6aee17c4b4aa096421f33059237
Autor:
Yang-Cheng, Lee, Yueh-Shan, Weng, Hsiao-Yu, Wang, Fei-Ting, Hsu, Fu-Shin, Chueh, Jeng-Yuan, Wu, Wei-Lung, Chen, Jiann-Hwa, Chen
Publikováno v:
Anticancer Research. 42:3825-3833
Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, and treatment outcomes are still poor. Magnolol, a hydroxylated biphenyl isolated from Magnolia officinalis, was found to be effective against hepatocellular carcino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::549d108dd35177df45f4970f158972fb
https://doi.org/10.21873/anticanres.15873
https://doi.org/10.21873/anticanres.15873
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0225938 (2019)
OBJECTIVE:This study is aimed toward establishing a decision-making model with multiple criteria for appraisal and reimbursement to compare the attitudes of different stakeholders toward various dimensions and criteria and to evaluate the five target
Externí odkaz:
https://doaj.org/article/830a468ad0064629ae67324df98edce7
Publikováno v:
In Vivo
Background/Aim: The combination of bevacizumab and atezolizumab (Bev-Ate) has been established as a standard first-line systemic treatment option for unresectable hepatocellular carcinoma (HCC) since 2020. This study examined the outcomes of HCC pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bfa31660e30cca3d8a906c2bc697d9d
https://europepmc.org/articles/PMC9843751/
https://europepmc.org/articles/PMC9843751/
Publikováno v:
Medicina, Vol 56, Iss 5, p 212 (2020)
Background and objective: BRCA1 and BRCA2 are associated with many cancer types in addition to hereditary breast and ovarian cancers. However, their relation to lung cancer remains to be explored. Materials and Methods: Observation studies were syste
Externí odkaz:
https://doaj.org/article/b0d761105f454efa94f2dbf5863c6e09
Publikováno v:
Anticancer research. 42(8)
Breast cancer (BC) is the most common cancer and second leading cause of death in women worldwide. Triple-negative breast cancer (TNBC) is the most aggressive type of BC, while the treatment option is limited and has long been considered as a major u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d81e6542a63ee1e79371a80573696483
https://pubmed.ncbi.nlm.nih.gov/35896246
https://pubmed.ncbi.nlm.nih.gov/35896246
Autor:
Yi-Lin Chen, Chung-Ta Lee, Cheng-Chan Lu, Shu-Ching Yang, Wan-Li Chen, Yang-Cheng Lee, Chung-Hsien Yang, Shu-Ling Peng, Wu-Chou Su, Nan-Haw Chow, Chung-Liang Ho
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0158125 (2016)
Analyzing EGFR mutations and detecting ALK gene fusion are indispensable when planning to treat pulmonary adenocarcinoma. Malignant pleural effusion (MPE) is a devastating complication of lung cancer and sometimes the only source for mutation analysi
Externí odkaz:
https://doaj.org/article/7a14b63f0dd94b5587304458801af390
Autor:
Hsueh-Chien Chiang, Yang-Cheng Lee, Ting-Tsung Chang, Yih-Jyh Lin, Hung-Tsung Wu, Chung-Teng Wang, Chiung-Yu Chen, Po-Jun Chen, Ming-Tsung Hsieh, Sheng-Hsiang Lin, Shang-Hung Chen, Chiao-Hsiung Chuang, I-Chin Wu, Tzu-Chun Hong, Juei-Seng Wu, Meng-Zhi Han, Wei-Ting Chen, Chien-Ming Chiang, Kuan-Kai Hung, Hsin-Yu Kuo
Publikováno v:
Cancers
Volume 15
Issue 3
Pages: 854
Volume 15
Issue 3
Pages: 854
Immune checkpoint inhibitors (ICIs) combined with multitarget tyrosine kinase inhibitors (MTKIs) exert a synergistic effect and are effective in unresectable hepatocellular carcinoma (uHCC). However, precise data regarding the real-world clinical app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa9ae599eb8c5e7891fbbb910cf959c
https://doi.org/10.3390/cancers15030854
https://doi.org/10.3390/cancers15030854